Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC Astellas Pharma US, Inc. , a U.S. Subsidiary of Tokyo-centered Astellas Pharma Inc. , announced that the U today.S. The application has been granted Priority Review status, and an FDA decision can be expected in the second quarter of 2013. Related StoriesMeat-rich diet plan may increase kidney cancers riskOvarian cancer patients with a brief history of oral contraceptive make use of possess better outcomesFDA grants accelerated approval for Tagrisso to take care of patients with advanced NSCLC ‘We are pleased the FDA granted an expedited six-month overview of our application because lung cancers is among the most common and deadly cancers,’ said Stephen Eck , M.D., Ph.D., vice president, head of Medical Oncology, Astellas Pharma Global Development, Inc.Those that raise their voices are denounced in the web for being unpatriotic. You have to put up with a complete lot.S. Food and Drug Administration recently accepted CREON in a 36,000 lipase-unit dosage to treat sufferers with exocrine pancreatic insufficiency due to cystic fibrosis, swelling of the pancreas that lasts quite a long time , removal of some or all of the pancreas , or various other conditions. This new strength is the highest dosage of pancreatic enzyme replacement therapy available and accepted by the FDA. ‘Patients with EPI require substitute of enzymes to help them break down food into nutrients,’ stated Dr. David C. Whitcomb , Chief, Division of Gastroenterology, Nutrition and Hepatology, University of Pittsburgh.’ Related StoriesNGN3-expressing cells in adult individual pancreas offer desire to diabeticsHealthcare technology sociable event of the year opens entriesAddressing quality of life needs in prostate tumor: an interview with Professor Louis Denis Exocrine pancreatic insufficiency may be the inability of the pancreas to produce enzymes that assist in the digestion of meals.